NO309964B1 - Anvendelse av melatoninderivater for fremstilling av et medikament for behandling av søvnforstyrrelser - Google Patents
Anvendelse av melatoninderivater for fremstilling av et medikament for behandling av søvnforstyrrelser Download PDFInfo
- Publication number
- NO309964B1 NO309964B1 NO944339A NO944339A NO309964B1 NO 309964 B1 NO309964 B1 NO 309964B1 NO 944339 A NO944339 A NO 944339A NO 944339 A NO944339 A NO 944339A NO 309964 B1 NO309964 B1 NO 309964B1
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- sleep disorders
- sleep
- melatonin
- methyl
- Prior art date
Links
- 208000019116 sleep disease Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims description 9
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical class COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract description 17
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002974 melatonin derivative Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 9
- RKHCTAKUYDTFHE-UHFFFAOYSA-N n-[2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl]acetamide Chemical compound C1=C(Cl)C(OC)=CC2=C1NC=C2C(C)CNC(C)=O RKHCTAKUYDTFHE-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 16
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 11
- 229960003987 melatonin Drugs 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- RKHCTAKUYDTFHE-QMMMGPOBSA-N ly-156,735 Chemical compound C1=C(Cl)C(OC)=CC2=C1NC=C2[C@@H](C)CNC(C)=O RKHCTAKUYDTFHE-QMMMGPOBSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- -1 bag Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 4
- 206010047139 Vasoconstriction Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000004620 sleep latency Effects 0.000 description 4
- 208000020685 sleep-wake disease Diseases 0.000 description 4
- 230000025033 vasoconstriction Effects 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229940097276 5-methoxytryptamine Drugs 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002613 pineal body hormone Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/154,332 US5654325A (en) | 1993-11-18 | 1993-11-18 | Melatonin derivatives for use in treating sleep disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO944339D0 NO944339D0 (no) | 1994-11-14 |
| NO944339L NO944339L (no) | 1995-05-19 |
| NO309964B1 true NO309964B1 (no) | 2001-04-30 |
Family
ID=22550932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO944339A NO309964B1 (no) | 1993-11-18 | 1994-11-14 | Anvendelse av melatoninderivater for fremstilling av et medikament for behandling av søvnforstyrrelser |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5654325A (cs) |
| EP (1) | EP0655243B1 (cs) |
| JP (1) | JPH07196493A (cs) |
| KR (1) | KR950013508A (cs) |
| CN (1) | CN1092958C (cs) |
| AT (1) | ATE222491T1 (cs) |
| AU (1) | AU684313B2 (cs) |
| CA (1) | CA2135709C (cs) |
| CZ (1) | CZ288835B6 (cs) |
| DE (1) | DE69431199T2 (cs) |
| DK (1) | DK0655243T3 (cs) |
| ES (1) | ES2181702T3 (cs) |
| HU (1) | HUT72069A (cs) |
| IL (1) | IL111580A (cs) |
| NO (1) | NO309964B1 (cs) |
| NZ (1) | NZ264892A (cs) |
| PH (1) | PH31098A (cs) |
| PT (1) | PT655243E (cs) |
| RU (1) | RU2146140C1 (cs) |
| SG (1) | SG50505A1 (cs) |
| ZA (1) | ZA948927B (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0748627A3 (en) * | 1995-06-14 | 1997-05-21 | Lilly Co Eli | Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate |
| CA2357114C (en) * | 2001-03-22 | 2010-06-29 | Pooger Properties Ltd. | Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| WO2002079153A1 (en) * | 2001-03-28 | 2002-10-10 | Biocatalytics, Inc. | Method for producing tryptamine derivatives |
| IL144900A (en) * | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
| CA2500198A1 (en) * | 2002-09-26 | 2004-04-08 | Pooger Properties Limited | Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder |
| JP4933097B2 (ja) | 2003-12-19 | 2012-05-16 | 株式会社メニコン | 糖尿病および糖尿病合併症の治療・改善方法 |
| WO2005062851A2 (en) * | 2003-12-22 | 2005-07-14 | Pappolla Miguel A | Indole-3-propionamide and derivatives thereof |
| CA2556753C (en) * | 2004-02-20 | 2014-11-25 | Lifescape Biosciences Incorporated | Compositions and methods for sleep regulation |
| DE102005008312A1 (de) * | 2005-02-17 | 2006-08-24 | Birds Pharma Gmbh Berolina Innovative Research & Development Services | Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]acatamide und deren pharmazeutisch verträglicher Salze sowie diese Verbindungen enthaltende Arzneimittel |
| US20060223877A1 (en) * | 2005-03-31 | 2006-10-05 | Zemlan Frank P | Methods of treatment utilizing certain melatonin derivatives |
| TWI402261B (zh) * | 2006-06-19 | 2013-07-21 | Takeda Pharmaceutical | 三環化合物及其醫藥組成物 |
| ES2324849A1 (es) * | 2007-10-25 | 2009-08-17 | Ferrer Internacional, S.A. | Compuestos de indano. |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4087444A (en) * | 1976-09-08 | 1978-05-02 | Eli Lilly And Company | Amides as ovulation inhibitors |
| IT1148618B (it) * | 1982-10-11 | 1986-12-03 | Polifarma Spa | Procedimento enzimatico per la produzione di acido 3-indolpiruvico e utilizzazione farmaceutica di questo |
| EP0126630B1 (en) * | 1983-05-18 | 1987-09-16 | Monash University | The use of melatonin for the manufacture of a medicament |
| US4600723A (en) * | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| US4614807A (en) * | 1984-10-04 | 1986-09-30 | Eli Lilly And Company | 6,7-dihalomelatonins |
| US4687763A (en) * | 1985-02-25 | 1987-08-18 | Massachusetts Institute Of Technology | Composition and method for increasing levels or release of brain serotonin |
| US4997845A (en) * | 1987-02-02 | 1991-03-05 | Eli Lilly And Company | β-alkylmelatonins as ovulation inhibitors |
| US5093352A (en) * | 1988-11-14 | 1992-03-03 | Whitby Research, Inc. | Antidepressant agents |
| AU616907B2 (en) * | 1987-08-17 | 1991-11-14 | Whitby Research, Inc. | Melatonin analogues |
| JPH0418034A (ja) * | 1990-05-11 | 1992-01-22 | Kanegafuchi Chem Ind Co Ltd | 点眼組成物 |
| US5242941A (en) * | 1990-12-04 | 1993-09-07 | State Of Oregon | Methods of treating circadian rhythm disorders |
| IT1251544B (it) * | 1991-05-13 | 1995-05-17 | Gabriele Biella | Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico |
| PT100973A (pt) * | 1991-10-18 | 1994-06-30 | Alza Corp | Dispositivo e composicoes farmaceuticas para a administracao de melatonina por via transdermica |
| US5196435A (en) * | 1991-11-21 | 1993-03-23 | Eli Lilly And Company | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma |
| IT1254995B (it) * | 1992-06-24 | 1995-10-11 | Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani | |
| IT1255199B (it) * | 1992-07-01 | 1995-10-20 | Franco Fraschini | Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani |
| US5449683A (en) * | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
-
1993
- 1993-11-18 US US08/154,332 patent/US5654325A/en not_active Expired - Fee Related
-
1994
- 1994-11-10 CZ CZ19942765A patent/CZ288835B6/cs not_active IP Right Cessation
- 1994-11-10 IL IL11158094A patent/IL111580A/xx not_active IP Right Cessation
- 1994-11-10 AU AU77777/94A patent/AU684313B2/en not_active Ceased
- 1994-11-10 NZ NZ264892A patent/NZ264892A/en not_active IP Right Cessation
- 1994-11-10 ZA ZA948927A patent/ZA948927B/xx unknown
- 1994-11-11 KR KR1019940029487A patent/KR950013508A/ko active Search and Examination
- 1994-11-14 NO NO944339A patent/NO309964B1/no not_active IP Right Cessation
- 1994-11-14 CA CA002135709A patent/CA2135709C/en not_active Expired - Fee Related
- 1994-11-15 PH PH49380A patent/PH31098A/en unknown
- 1994-11-16 RU RU94040886A patent/RU2146140C1/ru not_active IP Right Cessation
- 1994-11-16 AT AT94308466T patent/ATE222491T1/de not_active IP Right Cessation
- 1994-11-16 PT PT94308466T patent/PT655243E/pt unknown
- 1994-11-16 ES ES94308466T patent/ES2181702T3/es not_active Expired - Lifetime
- 1994-11-16 DK DK94308466T patent/DK0655243T3/da active
- 1994-11-16 EP EP94308466A patent/EP0655243B1/en not_active Expired - Lifetime
- 1994-11-16 SG SG1996002927A patent/SG50505A1/en unknown
- 1994-11-16 DE DE69431199T patent/DE69431199T2/de not_active Expired - Fee Related
- 1994-11-17 HU HU9403300A patent/HUT72069A/hu not_active Application Discontinuation
- 1994-11-17 CN CN94118946A patent/CN1092958C/zh not_active Expired - Fee Related
- 1994-11-17 JP JP6283275A patent/JPH07196493A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG50505A1 (en) | 1998-07-20 |
| JPH07196493A (ja) | 1995-08-01 |
| CN1107701A (zh) | 1995-09-06 |
| PH31098A (en) | 1998-02-05 |
| ZA948927B (en) | 1996-05-10 |
| AU7777794A (en) | 1995-05-25 |
| NO944339L (no) | 1995-05-19 |
| NZ264892A (en) | 1997-07-27 |
| RU94040886A (ru) | 1996-09-20 |
| CA2135709A1 (en) | 1995-05-19 |
| RU2146140C1 (ru) | 2000-03-10 |
| HU9403300D0 (en) | 1995-01-30 |
| US5654325A (en) | 1997-08-05 |
| DE69431199T2 (de) | 2003-03-27 |
| NO944339D0 (no) | 1994-11-14 |
| ES2181702T3 (es) | 2003-03-01 |
| CN1092958C (zh) | 2002-10-23 |
| CA2135709C (en) | 2007-01-02 |
| DE69431199D1 (de) | 2002-09-26 |
| DK0655243T3 (da) | 2002-10-07 |
| ATE222491T1 (de) | 2002-09-15 |
| KR950013508A (ko) | 1995-06-15 |
| CZ276594A3 (en) | 1995-07-12 |
| IL111580A (en) | 1999-10-28 |
| IL111580A0 (en) | 1995-01-24 |
| EP0655243A3 (en) | 1995-10-11 |
| PT655243E (pt) | 2002-11-29 |
| HUT72069A (en) | 1996-03-28 |
| EP0655243A2 (en) | 1995-05-31 |
| AU684313B2 (en) | 1997-12-11 |
| EP0655243B1 (en) | 2002-08-21 |
| CZ288835B6 (cs) | 2001-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5521166A (en) | Antiprogestin cyclophasic hormonal regimen | |
| CA2075904C (en) | Method of treating pre-menstrual syndrome | |
| EP0977558B1 (en) | Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors | |
| AU760540B2 (en) | Anti-estrogen plus progestin containing oral contraceptives | |
| NO309964B1 (no) | Anvendelse av melatoninderivater for fremstilling av et medikament for behandling av søvnforstyrrelser | |
| JPH07196500A (ja) | 閉経期後症候群に関連する血管運動症状および併発性心理的障害を抑制するための医薬組成物 | |
| US6180657B1 (en) | Melatonin derivatives for use in treating desynchronization disorders | |
| CA2081344C (en) | Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke | |
| BG99167A (bg) | Фармацевтични състави за ректално приложение на адкилсулфонамиди- агонисти на 5-нт долу 1 | |
| EP1545511B1 (en) | Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder | |
| AU719501B2 (en) | Melatonin agonists for treating benign prostatic hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |